{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-034220","form_type":"8-K","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2025-04-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.037644+00:00","generated_at":"2026-05-23T15:58:01.292724+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"Cara Therapeutics issues investor deck for pending merger with Tvardi (STAT3 fibrosis program)","bullets":["Merger with Tvardi Therapeutics (STAT3 inhibitor developer for fibrosis) announced Dec 17, 2024; closing conditions remain.","Investor presentation shared with potential investors outlines Tvardi's clinical pipeline and post-combination strategy.","No new financial terms disclosed; forward-looking statements caution on risks related to closing timing and regulatory submissions.","Tvardi focuses on oral small-molecule STAT3 therapies for fibrosis-driven diseases with significant unmet need."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-034220","json":"https://secwatch.observer/filing/0001104659-25-034220.json","markdown":"https://secwatch.observer/filing/0001104659-25-034220.md","text":"https://secwatch.observer/filing/0001104659-25-034220.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465925034220/0001104659-25-034220-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465925034220/tm2512145d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T15:58:01.292724+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}